Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Current Liabilities: 2011-2024

Historic Total Current Liabilities for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $55.5 million.

  • Adma Biologics' Total Current Liabilities rose 25.81% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year increase of 25.81%. This contributed to the annual value of $55.5 million for FY2024, which is 11.52% up from last year.
  • Per Adma Biologics' latest filing, its Total Current Liabilities stood at $55.5 million for FY2024, which was up 11.52% from $49.8 million recorded in FY2023.
  • Over the past 5 years, Adma Biologics' Total Current Liabilities peaked at $55.5 million during FY2024, and registered a low of $19.9 million during FY2020.
  • Moreover, its 3-year median value for Total Current Liabilities was $49.8 million (2023), whereas its average is $48.2 million.
  • Data for Adma Biologics' Total Current Liabilities shows a peak YoY surged of 52.29% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Adma Biologics' Total Current Liabilities stood at $19.9 million in 2020, then soared by 52.29% to $30.4 million in 2021, then climbed by 29.26% to $39.3 million in 2022, then rose by 26.84% to $49.8 million in 2023, then climbed by 11.52% to $55.5 million in 2024.